Burzynski Clinic

• Burzynski Clinic is a cancer treatment center based in Houston, Texas.
• Founded in 1977 by Dr. Stanislaw Burzynski.
• Nationally and internationally recognized for offering innovative and personalized cancer therapies.

Dr. Burzynski

• Physician and researcher focused on biologically active peptides and cancer.
• Discovered and developed Antineoplastons, used in FDA-approved clinical trials.
• Has treated over 10,000 patients and holds hundreds of patents worldwide related to his work.

Treatment philosophy

• Emphasis on personalized cancer care rather than "one-size-fits-all" treatment.
• Uses molecular and genetic information about each patient's cancer to guide therapy.
• Aims to address the root causes of cancer at the cellular and genetic level.
• Focus on maximizing treatment effectiveness while minimizing toxicity and side effects.
• Care is inspired by the Hippocratic principle: *"First, do no harm."*

Types of therapies offered (high-level)

• Personalized, targeted cancer therapies based on each patient's genetic and molecular profile.
• Antineoplaston (ANP) medications, including phenylbutyrate (PB) in tablet form and investigational infusions under applicable laws.
• Combination plans that may include:
• ANP group medications.
• FDA-approved targeted therapies.
• Conventional options such as low-dose chemotherapy when clinically appropriate.
• Options designed to be as gentle as possible while remaining therapeutically active.

Approach to patient care

• Each patient receives an individualized treatment plan.
• Emphasis on preserving dignity and quality of life during treatment.
• Ongoing supervision and follow-up, including coordination with the patient's local physicians when they return home.

Note: The clinic's therapies, including Antineoplastons and targeted combinations, are specialized medical treatments. Specific suitability, protocols, and potential benefits or risks must always be discussed directly with the clinic's medical team.

Role of diagnostics in treatment planning

• By identifying the specific genes and pathways involved in a patient's cancer, the clinic aims to:
• Select therapies that directly address those abnormalities.
• Avoid or reduce use of treatments that are unlikely to help.
• Improve the precision and potential effectiveness of care.

Non-toxic and lower-toxicity options

• Diagnostic insights are used to explore non-toxic or lower-toxicity alternatives as appropriate.
• When possible, the clinic seeks to avoid or limit reliance on traditional high-toxicity chemotherapy.

Early detection and ongoing monitoring

• The clinic emphasizes the value of early detection when feasible.
• Advanced molecular diagnostics may help detect disease activity earlier than some traditional methods.
• Diagnostic and monitoring services are also used to:
• Track response to treatment.
• Adjust or refine treatment plans over time.

Details of which tests are used, how often they are repeated, and how results may affect treatment are determined individually by the clinic's medical team for each patient.

• Burzynski Clinic
• 9432 Katy Freeway
• Houston, Texas 77055
• United States

Main contact details

• Main clinic phone (USA and international): +1 (713) 335-5697
• Direct line (as listed in admissions contact details): +1 (713) 335-5650
• Fax: +1 (713) 335-5651
• Main clinic email: info@burzynskiclinic.com
• Website: https://www.burzynskiclinic.com

Clinic hours

• Working hours: 9:00 am – 5:00 pm, Monday through Thursday.
• Closed: Fridays, Saturdays, and Sundays.

Prospective patients

• Prospective cancer patients and their advocates can start the process by submitting an inquiry form via the clinic's website.
• The clinic indicates that it typically responds to inquiries within 24–48 hours or by the next business day.
• When you reach out, you may be asked for pathology reports and other medical records so the medical team can review your case.

Departments and additional contacts (selected)

• Human Resources: jobs@burzynskiclinic.com
• Media / public relations / interview and speaker requests: pr@burzynskiclinic.com
• Business, financial, and administrative information: corporate@burzynskiclinic.com

For any urgent or case-specific questions about treatment options, scheduling, or medical suitability, contact the clinic directly by phone or through the prospective patient inquiry process on the website.

Personalized, patient-centered experience

• Treatment plans are developed with attention to medical, emotional, and practical needs.
• The team aims to provide a bespoke, patient-centered experience from the first contact through follow-up care.

Medical and nursing support

• Patients receive care from a dedicated medical team and nursing staff.
• Support includes:
• Ongoing guidance and coordination of care.
• Assistance with questions about treatment and logistics.
• Emotional support throughout the treatment journey.

Streamlined, lower-stress coordination

• The clinic works to make scheduling and coordination as smooth as possible.
• Systems are designed to reduce disruption to daily life and to minimize administrative burden for patients and families.

Home and remote oncology services

• For select cases, the clinic may provide home and remote oncology services, which can include:
• Telemedicine consultations.
• Home visits and mobile diagnostics, when available and appropriate.
• These options are intended to provide greater convenience and privacy while maintaining close medical oversight.

Follow-up after returning home

• After in-clinic treatment, Burzynski Clinic continues to supervise care in coordination with the patient's local physicians.
• Follow-up can include:
• Monitoring the patient's progress.
• Reviewing test results.
• Adjusting treatment plans as needed.

Availability of concierge services, home visits, and remote options may vary by patient location, clinical situation, and current clinic policies. Patients should confirm current options directly with the clinic.

Antineoplaston (ANP) group medications

• The clinic uses medications from the Antineoplaston (ANP) group as part of its approach.
• One ANP medication, PB (phenylbutyrate) in tablet form, can be prescribed off-label when appropriate.
• Additional ANP medications are available as investigational infusions for advanced patients under specific regulatory pathways (e.g., Texas Right to Try Law and clinical trials, where applicable).

Targeted therapies

• Treatment plans often combine ANP medications with FDA-approved targeted therapies.
• Targeted therapies focus on specific genes or proteins associated with cancer growth and survival.
• The clinic reports extensive experience using phenylbutyrate and other targeted agents in combination treatment plans.

Conventional therapies

• Some patients may also receive conventional therapies, such as:
• Low-dose chemotherapy.
• Other oncologic medications.
• Surgery, radiation therapy, and specialized imaging (MRI, CT, PET) are typically provided at other local medical facilities and coordinated as part of the patient's overall care.

Goals of treatment plans

• Affect a broad range of cancer-related genetic abnormalities using a combination of ANP group medications and targeted therapies.
• Maximize effectiveness while minimizing toxicity and side effects.
• Preserve or improve the patient's quality of life during and after treatment.

Specific treatment combinations, eligibility for investigational therapies, and expected risks and benefits are determined on a case-by-case basis by the clinic's physicians after reviewing each patient's records and test results.

Ask anyway — the agent will say plainly that it is not published rather than guess.